Professor, Department of Pharmacy Practice
Ivo Abraham is a professor (part-time) in the Department of Pharmacy Practice. He has also served on the faculty of Case Western Reserve University (Cleveland, Ohio), University of Virginia (Charlottesville, Va.), and (part-time) Katholieke Universiteit Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, Fla.), Rijksuniversiteit Groningen (Groningen, The Netherlands), University of Pennsylvania (Philadelphia, Penn.), and Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan). He has lectured, consulted, and conducted research throughout the Americas, Europe, the Asia-Pacific region, and Africa. Being part-time, he divides his time between the University of Arizona and Matrix45, a biopharmaceutical research and consulting company, where he serves as chief scientist.
For the past decade or so, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research, in particular how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes. However, instead of merely evaluating effectiveness (does the treatment work?), the work of his research group addresses the equally important questions of when does the treatment work (and when not), what influences whether the treatment works, why does the treatment work in some patients but not in others, why does the treatment work with some clinicians but not with others, why is the treatment tolerated by some patients but not by others, and how much of patient outcomes is related to patient vs. clinician or treatment center? In this process, his group uses a comprehensive framework of treatment patterns and outcomes assessment, vulnerability profiling, hierarchical modeling, (non-)responder analysis, and pharmacovigilance and drawing methodologies and statistical models from other disciplines into biomedical research.
2021
AlRawashdh N, Sweasy J, Erstad B, McBride A, Persky DO, Abraham I. "Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017)." Ann Hematol. 2021;100(10):2501-2512. PMID: 34279676
Alkhatib N, Sweitzer NK, Lee CS, et al. "Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure." Am J Cardiovasc Drugs. 2021;21(2):205-217. PMID: 32710439
Moore L, Bartels T, Persky DO, Abraham I, Kumar A, McBride A. "Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience." Support Care Cancer. 2021;29(8):4867-4874. PMID: 33547525
Hamarneh D, Alkhatib N, Denhaerynck K, et al. "Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients." Curr Med Res Opin. 2021;37(3):367-375. PMID: 33467935
Kim H-J, Abraham I. "Determinants of the Higher Prevalence and Severity of Subjective Cognitive Impairment in Cancer Patients Compared to Healthy Subjects: Fatigue and Stress." Clin Nurs Res. 2021;30(6):809-817. PMID: 32959682
Faulkner KM, Macdonald K, Abraham I, Alhossan A, Lee CS. "'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis." Expert Rev Clin Immunol. 2021;17(1):73-83. PMID: 33307892
Choi BM, Abraham I. "The Decline in e-Cigarette Use Among Youth in the United States-An Encouraging Trend but an Ongoing Public Health Challenge." JAMA Netw Open. 2021;4(6):e2112464. PMID: 34097051
Alamer A, Alrashed AA, Alfaifi M, et al. "Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis." Curr Med Res Opin. 2021;37(7):1085-1097. PMCID: PMC8146299 PMID: 33890544
Alamer AA, Almulhim AS, Alrashed AA, Abraham I. "Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic." Healthcare (Basel). 2021;9(2). PMCID: PMC7912160 PMID: 33525596
Mohzari YA, Alshuraim R, Asdaq SMohammed B, et al. "Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis." J Infect Public Health. 2021;15(1):1-6. PMID: 34852307